{
  "patientId": "RC-003",
  "demographics": {
    "name": "Maria Garcia",
    "dob": "1970-11-10",
    "gender": "Female",
    "address": "789 Pine Street, Anytown, USA",
    "phone": "555-9876",
    "insurance": "Aetna - Policy #AETN-MG-701110",
    "referringPhysician": "Dr. Susan Miller (Gastroenterology)",
    "emergencyContact": "Jose Garcia (Husband) - 555-6789",
    "advanceDirectives": "Full Code (On File, verified 04/25/2025)",
    "supportServices": "Pre-operative ostomy education provided by wound/ostomy nurse. Nutrition consult for managing GI side effects during chemoradiation.",
    "mobility": "Ambulatory without assistance. ECOG Performance Status 0."
  },
  "diagnosis": {
    "primary": "Adenocarcinoma of the Rectum",
    "datePathologicDiagnosis": "04/10/2025 (Initial Biopsy)",
    "pathologicStage": "Clinical Stage: cT3 N0 M0. Pathologic Stage (post-neoadjuvant chemoRT): ypT2 N0 M0.",
    "symptomsAtPresentation": "Patient presented with a 2-month history of intermittent bright red blood per rectum and a persistent feeling of incomplete evacuation (tenesmus).",
    "pathologyFindings": [
      "Initial Biopsy (04/10/2025): Moderately differentiated adenocarcinoma.",
      "Surgical Pathology (Low Anterior Resection, 07/15/2025): Moderately differentiated adenocarcinoma, 2.5 cm. Tumor invades into but not through the muscularis propria (ypT2). No lymphovascular invasion. 0 of 14 regional lymph nodes positive (ypN0). All margins negative. Tumor Regression Grade (TRG): 2 (Moderate response)."
    ],
    "priorProcedures": "Low Anterior Resection (LAR) for rectal cancer performed on 07/15/2025.",
    "relevantHistory": "No significant family history of colorectal cancer. No personal history of inflammatory bowel disease.",
    "baselineStatus": "ECOG 0. Patient is otherwise healthy and motivated for treatment."
  },
  "treatmentPlan": {
    "radOnc": "Dr. Linda White",
    "medOnc": "Dr. Michael Chen",
    "surgOnc": "Dr. James Miller",
    "treatmentSite": "Rectum + Mesorectum + Pelvic Lymph Nodes",
    "intent": "Neoadjuvant followed by Adjuvant",
    "modality": "Neoadjuvant concurrent Chemoradiation, followed by Surgical Resection, followed by Adjuvant Chemotherapy.",
    "totalDose": "45 Gy",
    "fractionation": "25 fx",
    "rtRxDetails": "45 Gy in 25 fractions (1.8 Gy/fx) to the pelvis.",
    "targetVolumeSummary": "The PTV encompasses the primary rectal tumor, the entire mesorectum, and the presacral and internal iliac nodal basins.",
    "techniqueSummary": "3D-Conformal Radiation Therapy (3D-CRT) using a 3-field technique (PA and opposed laterals). Patient is treated in the prone position on a belly board to displace the small bowel anteriorly, out of the radiation fields.",
    "detailedConcurrentChemo": "Concurrent Capecitabine (825 mg/mÂ² PO BID) taken on radiation treatment days. Adjuvant chemotherapy with 6 months of FOLFOX planned post-operatively.",
    "medications": [
      "Capecitabine (Xeloda) as prescribed.",
      "Ondansetron (Zofran) 8mg PO PRN for nausea.",
      "Loperamide (Imodium) 2mg PO PRN for diarrhea.",
      "Mometasone 0.1% cream for perineal skin care."
    ],
    "therapistAlerts": [
      "Patient is treated PRONE on a belly board. Verify patient orientation daily.",
      "Patient must adhere to a full bladder / empty rectum protocol to minimize dose to small bowel.",
      "Patient is on concurrent oral chemotherapy (Capecitabine); high risk for diarrhea and skin reaction. Assess symptoms daily.",
      "Monitor for skin reaction in the gluteal cleft and perineum. Provide proactive skin care instructions.",
      "Daily kV imaging for setup verification is critical."
    ]
  },
  "radiationOncologyData": {
    "ctSimulation": {
      "simulationDate": "04/25/2025",
      "setupInstructions": "Patient positioned prone on a belly board with a prone head pillow. Arms are down at sides. Patient instructed to have a comfortably full bladder and empty rectum.",
      "immobilization": "Prone belly board, prone head pillow.",
      "referenceMarks": "3-point tattoos at isocenter projections (posterior and bilateral laterals).",
      "scanner": "GE Discovery RT",
      "ctNotes": "CT simulation for neoadjuvant pelvic radiation therapy. Prone position on the belly board successfully displaced the small bowel anteriorly. Surgical clips from biopsy site are visible. Fused with diagnostic MRI for accurate tumor delineation."
    },
    "dosimetry": {
      "planId": "MGRC003_Rectal_3D",
      "planStatus": "Final - Approved by Dr. Linda White (04/28/2025)",
      "rx": "45 Gy / 25 fx",
      "technique": "3D-CRT (3-Field PA/Lats)",
      "energy": "10MV",
      "tps": "Eclipse v16",
      "constraints": "Femoral Head Max < 40 Gy (achieved L: 35, R: 36 Gy); Bladder V40Gy < 50% (achieved 45%); Small Bowel Max < 45 Gy (achieved 44.8 Gy).",
      "planNotes": "Neoadjuvant chemoradiation for cT3N0 rectal cancer. Prone setup utilized for bowel sparing. Standard 3-field technique provides excellent target coverage while meeting OAR constraints.",
      "igrtProtocol": {
        "frequency": "Daily",
        "type": "kV Imaging (Orthogonal Pair)",
        "alignment": "Match to pelvic bony anatomy (sacrum, acetabula).",
        "tolerances": "Translational: +/- 3mm"
      },
      "fieldDetails": [
        { "fieldName": "PA Pelvis", "fieldSize": "15.0 x 16.0 cm", "gantryAngle": "180", "collimatorAngle": "0", "couchAngle": "0", "energy": "10MV", "monitorUnits": 190, "ssd": "92.0 cm" },
        { "fieldName": "R Lat Pelvis", "fieldSize": "15.0 x 16.0 cm", "gantryAngle": "90", "collimatorAngle": "0", "couchAngle": "0", "energy": "10MV", "monitorUnits": 145, "ssd": "85.5 cm" },
        { "fieldName": "L Lat Pelvis", "fieldSize": "15.0 x 16.0 cm", "gantryAngle": "270", "collimatorAngle": "0", "couchAngle": "0", "energy": "10MV", "monitorUnits": 145, "ssd": "85.0 cm" }
      ]
    },
    "treatmentDelivery": {
      "fractions": [
        {
          "fractionNumber": 1, "totalFractions": 25, "date": "2025-05-01", "machine": "LINAC3", "therapistInitials": "JL, KW",
          "recordedFields": [{ "fieldName": "PA", "deliveredMu": 190 }, { "fieldName": "R Lat", "deliveredMu": 145 }, { "fieldName": "L Lat", "deliveredMu": 145 }],
          "energiesUsed": "10MV", "setupVerification": "Tolerances Met", "immobilizationDevicesChecked": "Prone belly board", "setupAdjustments": "None", "organTargetChecks": "kV images reviewed, match to sacrum good.", "imagingType": "kV Pair", "igrtMatchQuality": "Excellent", "igrtApprovedBy": "LW (Physician)",
          "patientTolerance": "Good", "generalSideEffects": "None", "siteSpecificSideEffects": "None", "painAssessment": "0/10", "patientConcerns": "Anxious about side effects.", "instructionsGiven": "Educated on oral chemotherapy schedule and side effects. Reinforced skin care and diet instructions.", "billingCodes": "77412, 77387", "dailyNotes": "Patient started neoadjuvant chemoRT. Tolerated first treatment well."
        },
        {
          "fractionNumber": 10, "totalFractions": 25, "date": "2025-05-14", "machine": "LINAC3", "therapistInitials": "JL, KW",
          "recordedFields": [{ "fieldName": "PA", "deliveredMu": 190 }, { "fieldName": "R Lat", "deliveredMu": 145 }, { "fieldName": "L Lat", "deliveredMu": 145 }],
          "energiesUsed": "10MV", "setupVerification": "Tolerances Met", "immobilizationDevicesChecked": "Prone belly board", "setupAdjustments": "None", "organTargetChecks": "kV match stable.", "imagingType": "kV Pair", "igrtMatchQuality": "Good", "igrtApprovedBy": "Therapist",
          "patientTolerance": "Good", "generalSideEffects": "Mild fatigue.", "siteSpecificSideEffects": "2-3 loose stools/day. Mild perineal erythema (Grade 1).", "painAssessment": "0/10", "patientConcerns": "Concerned about diarrhea.", "instructionsGiven": "Reinforced use of Loperamide and low-residue diet.", "billingCodes": "77412, 77387, 77427", "dailyNotes": "OTV today. Patient developing expected Grade 1 GI and skin toxicity. Managing well."
        },
        {
          "fractionNumber": 25, "totalFractions": 25, "date": "2025-06-04", "machine": "LINAC3", "therapistInitials": "JL, KW",
          "recordedFields": [{ "fieldName": "PA", "deliveredMu": 190 }, { "fieldName": "R Lat", "deliveredMu": 145 }, { "fieldName": "L Lat", "deliveredMu": 145 }],
          "energiesUsed": "10MV", "setupVerification": "Tolerances Met", "immobilizationDevicesChecked": "Prone belly board", "setupAdjustments": "None", "organTargetChecks": "Final kV images reviewed.", "imagingType": "kV Pair", "igrtMatchQuality": "Excellent", "igrtApprovedBy": "LW (Physician)",
          "patientTolerance": "Fair", "generalSideEffects": "Moderate fatigue.", "siteSpecificSideEffects": "Grade 2 diarrhea controlled with scheduled Loperamide. Grade 2 perineal dermatitis.", "painAssessment": "1/10 (skin soreness)", "patientConcerns": "Ready to be done and proceed with surgery.", "instructionsGiven": "End-of-treatment instructions provided. Side effects will resolve over the next 2-4 weeks. Surgical date confirmed.", "billingCodes": "77412, 77387, 77427", "dailyNotes": "Final fraction of neoadjuvant chemoRT completed. Patient tolerated the full course well. Will now have a recovery period before her planned Low Anterior Resection."
        }
      ]
    }
  },
  "progressNotes": [
    { "date": "04/12/2025", "author": "Dr. James Miller (Surg Onc)", "type": "Initial Consult", "summary": "Patient with new diagnosis of cT3N0 rectal adenocarcinoma. Reviewed imaging. The tumor is located mid-rectum and is amenable to a sphincter-sparing Low Anterior Resection (LAR). Neoadjuvant chemoradiation is recommended to downstage the tumor and reduce the risk of local recurrence. Referred to Medical and Radiation Oncology." },
    { "date": "04/20/2025", "author": "Dr. Linda White (Rad Onc)", "type": "Initial Consult", "summary": "Patient referred for neoadjuvant chemoRT for rectal cancer. Plan is for 45 Gy in 25 fractions to the pelvis with concurrent oral Capecitabine. We discussed the rationale, treatment setup (prone on belly board for small bowel sparing), and potential side effects (diarrhea, skin irritation, fatigue). Patient understands and wishes to proceed. CT simulation scheduled." },
    { "date": "06/04/2025", "author": "Dr. Linda White (Rad Onc)", "type": "End of Treatment Note", "summary": "Maria has completed her course of neoadjuvant chemoradiation. She experienced expected Grade 2 GI and skin toxicities, which were well-managed. She will now have a rest period of 8-10 weeks before proceeding with her scheduled LAR." },
    { "date": "07/20/2025", "author": "Dr. James Miller (Surg Onc)", "type": "Post-Op Note", "summary": "Patient is recovering well from her LAR. Final pathology shows an excellent response to neoadjuvant therapy, with downstaging to ypT2N0. All margins are clear. She will follow up with Medical Oncology to discuss adjuvant chemotherapy." }
  ]
}
